Tracking a new hope for Tough-to-Treat blood cancer patients
NCT ID NCT07320326
Summary
This study aims to collect real-world information on how well the drug elranatamab works for Chinese patients with advanced multiple myeloma that has stopped responding to other standard treatments. It will follow about 159 patients who are already receiving this drug as part of their regular care. The goal is to understand its effectiveness and impact on patients' lives in everyday medical practice.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TCE-RRMM are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Peking University People's Hospital
Beijing, Beijing Municipality, 100044, China
Conditions
Explore the condition pages connected to this study.